Phase 2 Pancreatic Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have signed and dated a consent form before any screening takes place
- You have been diagnosed with pancreatic cancer (specifically pancreatic adenocarcinoma) confirmed by a tissue or cell sample
- Your cancer was first diagnosed as having spread (metastatic) no more than 9 weeks before joining the study
- Doctors expect you to live for at least 3 months
- Scans show your cancer has spread to at least one other part of the body, and that spread can be measured on imaging
- You are in good enough general health to carry out daily activities with little or no limitation (confirm with trial site)
- You are able to understand and agree to follow the study requirements
- You are able to swallow and keep down oral (by mouth) medication without uncontrolled vomiting
- Your digestive system can absorb medications properly
- You have not previously received chemotherapy to treat your cancer after it spread, though treatment with a specific type of RAS-targeting drug is allowed
- If you did receive chemotherapy before your cancer spread, your cancer must have come back more than 12 months after finishing that treatment, and you must have no lasting side effects from it
- Your liver, kidneys, and other organs are working well enough (confirm with trial site)
- If you could become pregnant, you have a negative pregnancy test
- You agree to use the study-required methods to prevent pregnancy during the trial
Who may not be able to join:
- You have had major surgery within the last 4 weeks
- You have already received radiotherapy, surgery, chemotherapy, immunotherapy, or any experimental treatment for your cancer after it spread
- You have taken steroid medicines (by mouth, inhaled, or strong prescription skin treatments) recently within a timeframe based on the specific steroid used (confirm with trial site)
- You have previously been treated with gemcitabine or nab-paclitaxel for your pancreatic cancer
- You have a known inherited or acquired mutation in the BRCA gene (a gene linked to certain cancers)
- You have nerve damage causing symptoms (such as tingling or numbness) that are more than mild (confirm with trial site)
- You have a medical condition that requires you to regularly or frequently take steroid medicines
- You have had a serious allergic reaction to any of the drugs used in this study or their ingredients
- You are currently taking a drug called mifepristone or similar medicines that affect how the body processes steroids
- You have an uncontrolled health condition that could affect your safety or the study results
- You currently have an active HIV, hepatitis B, or hepatitis C infection
- You have cancer that has spread to the brain and has not been treated, or brain/spinal cancer spread that is not under control
- You have been diagnosed with another type of cancer within the past 3 years
- You are currently taking medications that are not allowed in this study (confirm with trial site)
- You are currently taking part in another cancer treatment study
- You have received a live vaccine within the last 30 days before the study begins
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Adrian Jubb, Corcept Therapeutics
Phone: (650) 815-1595
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Percent of Patients who Experience Dose Limiting Toxicity (DLT) (Part 1); Number of Patients with 1 or More Adverse Events (AEs) Leading to Study Drug Discontinuations or Dose Modifications (Part 1); Progression-Free Survival (PFS) (Part 2)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.